UCB/Sanofi Xyzal approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
UCB and Sanofi-Aventis plan to launch the antihistamine Xyzal (levocetirizine) in the U.S. in time for the fall allergy season, the companies said. FDA approved the once-daily H1 receptor antagonist May 25 for the relief of symptoms associated with seasonal and perennial allergic rhinitis and for the treatment of uncomplicated skin manifestations of chronic urticaria in adults and children 6 years of age and older. Firms plan to jointly promote Xyzal in the U.S. using a combined field force of 1,000 sales reps. Timing of the launch will fall just ahead of when UCB/Pfizer's Zyrtec (cetirizine) is scheduled to go off patent later this year. However, UCB/Sanofi could face competition from over-the-counter H1 receptor antagonists such as loratadine (Schering-Plough's Claritin and generics). Johnson & Johnson is planning to launch OTC Zyrtec in late 2007 after acquiring the OTC licensing rights through its purchase of Pfizer Consumer Healthcare in December...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.